CA1283047C - Stabilized plasminogen activator precursor and method of producing the same - Google Patents

Stabilized plasminogen activator precursor and method of producing the same

Info

Publication number
CA1283047C
CA1283047C CA000500493A CA500493A CA1283047C CA 1283047 C CA1283047 C CA 1283047C CA 000500493 A CA000500493 A CA 000500493A CA 500493 A CA500493 A CA 500493A CA 1283047 C CA1283047 C CA 1283047C
Authority
CA
Canada
Prior art keywords
precursor
salts
stabilizing
urokinase
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000500493A
Other languages
English (en)
French (fr)
Inventor
Kazuo Morimoto
Motoshi Sagane
Kazuhiro Ohara
Shusaku Narita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Application granted granted Critical
Publication of CA1283047C publication Critical patent/CA1283047C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA000500493A 1985-01-30 1986-01-28 Stabilized plasminogen activator precursor and method of producing the same Expired - Lifetime CA1283047C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17077/85 1985-01-30
JP60017077A JPS61176532A (ja) 1985-01-30 1985-01-30 プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法

Publications (1)

Publication Number Publication Date
CA1283047C true CA1283047C (en) 1991-04-16

Family

ID=11933913

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000500493A Expired - Lifetime CA1283047C (en) 1985-01-30 1986-01-28 Stabilized plasminogen activator precursor and method of producing the same

Country Status (6)

Country Link
US (1) US5075230A (enExample)
EP (1) EP0190041A3 (enExample)
JP (1) JPS61176532A (enExample)
KR (1) KR940000540B1 (enExample)
CA (1) CA1283047C (enExample)
ES (1) ES8802582A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940003056B1 (ko) * 1985-04-16 1994-04-13 가부시끼가이샤 미도리 쥬우지 우로키나제 전구체를 안정화시키는 방법
JPH0610139B2 (ja) * 1986-05-15 1994-02-09 エモリ ユニバーシティ 繊維素溶解性合成物混合物及び血管内の血餅溶解用薬剤
JPS62292729A (ja) * 1986-06-12 1987-12-19 Toyobo Co Ltd ヒト子宮組織由来プラスミノ−ゲン活性化因子製剤
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
CA2091544A1 (en) * 1992-03-26 1993-09-27 Shing F. Kwan Stabilization of functional proteins
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5137343B2 (enExample) * 1972-12-07 1976-10-15
US4245051A (en) * 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
NL7812336A (nl) * 1978-12-20 1980-06-24 Methanol Chemie Nederland Bereiding van spaanplaat.
JPS5668607A (en) * 1979-11-07 1981-06-09 Teikoku Hormone Mfg Co Ltd Medical preparation with storage stability
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
JPS58170354A (ja) * 1982-03-30 1983-10-06 Hitachi Ltd リニヤ・アクチユエ−タ
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0139447B1 (en) * 1983-09-13 1992-12-30 The Green Cross Corporation A process for preparing urokinase zymogen
EP0151996B1 (en) * 1984-01-30 1991-04-03 Asahi Kasei Kogyo Kabushiki Kaisha Process for the preparation of a double-chain plasminogen activator
KR940003056B1 (ko) * 1985-04-16 1994-04-13 가부시끼가이샤 미도리 쥬우지 우로키나제 전구체를 안정화시키는 방법

Also Published As

Publication number Publication date
ES551324A0 (es) 1988-08-16
JPS61176532A (ja) 1986-08-08
ES8802582A1 (es) 1988-08-16
EP0190041A2 (en) 1986-08-06
JPH0479326B2 (enExample) 1992-12-15
EP0190041A3 (en) 1988-09-28
US5075230A (en) 1991-12-24
KR860005884A (ko) 1986-08-13
KR940000540B1 (ko) 1994-01-24

Similar Documents

Publication Publication Date Title
EP0100982B1 (en) Novel purified plasminogen activator, process for its production and thrombolytic composition containing it
CA1217718A (en) Plasminogen activator derivatives
Nagai et al. Tadpole collagenase. Preparation and purification
EP0156169B1 (en) An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
US4495285A (en) Plasminogen activator derivatives
US4245051A (en) Human serum plasminogen activator
EP0123304B1 (en) A method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same
EP0217379B1 (en) Thrombolytic composition and a process for production thereof
Salem et al. Human coagulation factor Va is a cofactor for the activation of protein C.
JP2690944B2 (ja) 組織プラスミノーゲンアクチベーター活性を有するタンパク質の高濃度溶液
AOKI Preparation of Plasminogen Activator from Vascular Trees of Human Cadavers Its Comparison with Urokinase
GB2176702A (en) Tissue plasminogen activator
CA1094449A (en) Plasminogen activator complex
EP0190041A2 (en) Stabilized plasminogen activator precursor and method of producing the same
Salem et al. The light chain of factor Va contains the activity of factor Va that accelerates protein C activation by thrombin.
EP0726076B1 (en) Method of stabilizing protein c or activated protein c and stabilized composition
EP0200966B1 (en) Method of stabilizing urokinase precursor and dry preparation containing said precursor
EP0151996B1 (en) Process for the preparation of a double-chain plasminogen activator
RU2247777C2 (ru) Модифицированный активатор плазминогена урокиназного типа, последовательность днк, рекомбинантная плазмида, штамм-продуцент, способ получения модифицированного активатора плазминогена урокиназного типа и фармацевтическая композиция, обладающая тромболитическим действием
US4946785A (en) Method of suppressing the thermal degradation of urokinase
JPS60248621A (ja) 一本鎖組織プラスミノ−ゲンアクチベ−タ−の安定化方法
JPH0143549B2 (enExample)
CA1206903A (en) Process for the preparation of a plasminogen activator
Heimburger The mechanism of action of sstreptokinase
Masuko et al. Chloride-or bromide-dependent activation of nitrite reductase by freeze-thawing in a cell-free system of a denitrifier, Alcaligenes sp.

Legal Events

Date Code Title Description
MKLA Lapsed